Skip to main content
. 2023 Mar 30;17(9):1395–1409. doi: 10.1093/ecco-jcc/jjad056

Table 5.

Cumulative incidence of any polyp at 10 and 20 years of follow-up in patients with IBD, UC and CD.

Group IBD UC CD
IBD Comparators Risk difference UC Comparators Risk difference CD Comparators Risk difference
10-year cumulative incidence [95% CI]
Any polyp 4.3% [4.1–4.6] 3.3% [3.1–3.6] 1.0% [0.9; 1.1] 4.7% [4.4–5.0] 3.4% [3.2–3.7] 1.3% [1.1; 1.4] 3.4% [3.1–3.9] 3.0% [2.7–3.4] 0.4% [0.2; 0.6]
Tubular adenoma 3.2% [3.0–3.5] 2.6% [2.4–2.8] 0.6% [0.5; 0.8] 3.5% [3.2–3.7] 2.7% [2.5–2.9] 0.8% [0.6; 0.9] 2.7% [2.4–3.1] 2.4% [2.1–2.8] 0.3% [0.1; 0.5]
Sessile serrated polyps 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [0.0; 0.1]
Polyp unspecified with LGD 0.1% [0.1–0.2] 0.0% [0.0–0.1] 0.1% [0.0; 0.1] 0.1% [0.1–0.2] 0.1% [0.0–0.1] 0.1% [0.0; 0.1] 0.1% [0.0–0.1] 0.0% [0.0–0.0] 0.1% [0.0; 0.1]
Any advanced polyp 1.4% [1.3–1.6] 1.1% [0.9–1.2] 0.3% [0.3; 0.4] 1.6% [1.4–1.8] 1.1% [0.9–1.2] 0.5% [0.4; 0.6] 0.9% [0.8–1.2] 1.0% [0.8–1.3] –0.1% [–0.2; 0.0]
 Sessile serrated polyps with LGD 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.1] –0.0% [–0.0; 0.0]
 Sessile serrated polyps with HGD 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0]
 Traditional serrated adenomas 0.1% [0.1–0.2] 0.1% [0.1–0.1] 0.1% [0.0; 0.1] 0.2% [0.1–0.2] 0.1% [0.0–0.1] 0.1% [0.1; 0.1] 0.1% [0.1–0.2] 0.1% [0.1–0.3] –0.0% [–0.1; 0.0]
  Traditional serrated adenomas with LGD 0.0% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [–0.0; 0.0] 0.1% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [–0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.1] –0.0% [–0.0; 0.0]
  Traditional serrated adenomas with HGD 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0]
 Tubulovillous 1.1% [1.0–1.3] 0.9% [0.8–1.0] 0.3% [0.2; 0.3] 1.3% [1.1–1.5] 0.9% [0.8–1.1] 0.4% [0.3; 0.5] 0.8% [0.6–1.0] 0.8% [0.7–1.1] –0.0% [–0.1; 0.1]
  Tubulovillous with HGD 0.1% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [–0.0; 0.0] 0.1% [0.0–0.1] 0.1% [0.0–0.1] 0.0% [–0.0; 0.0] 0.1% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [0.0; 0.0]
 Villous 0.1% [0.1–0.1] 0.1% [0.0–0.1] 0.0% [0.0; 0.1] 0.1% [0.1–0.2] 0.1% [0.0–0.1] 0.1% [0.0; 0.1] 0.0% [0.0–0.1] 0.1% [0.0–0.1] –0.0% [–0.1; –0.0]
  Villous with HGD 0.0% [0.0–0.0] 0.0% [0.0–0.0] –0.0% [–0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.1] –0.0% [–0.0; 0.0]
  Tubulous with HGD 0.0% [0.0–0.1] 0.1% [0.0–0.1] –0.0% [–0.0; 0.0] 0.1% [0.0–0.1] 0.1% [0.0–0.1] –0.0% [–0.0; –0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [–0.0; 0.0]
 Polyp unspecified with
HGD		 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0]
20-year cumulative incidence [95% CI]
Any polyp 9.4% [8.8–10.1] 6.1% [5.6–6.6] 3.3% [3.2; 3.5] 10.7% [9.9–11.6] 6.4% [5.8–7.0] 4.4% [4.1; 4.6] 6.9% [6.1–7.8] 5.4% [4.7–6.3] 1.5% [1.2; 1.8]
Tubular adenoma 7.4% [6.9–8.0] 4.8% [4.4–5.3] 2.6% [2.4; 2.8] 8.3% [7.6–9.1] 5.0% [4.5–5.6] 3.3% [3.1; 3.5] 5.6% [4.9–6.5] 4.4% [3.7–5.1] 1.3% [1.0; 1.5]
Sessile serrated polyps 0.1% [0.1–0.2] 0.0% [0.0–0.1] 0.1% [0.1; 0.1] 0.2% [0.1–0.4] 0.0% [0.0–0.1] 0.1% [0.1; 0.2] 0.0% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [0.0; 0.1]
Polyp unspecified with LGD 0.3% [0.2–0.4] 0.1% [0.0–0.1] 0.2% [0.2; 0.2] 0.4% [0.2–0.6] 0.1% [0.1–0.2] 0.3% [0.2; 0.3] 0.1% [0.0–0.1] 0.0% [0.0–0.0] 0.1% [0.0; 0.1]
Any advanced polyp 3.2% [2.9–3.6] 2.1% [1.9–2.4] 1.1% [1.0; 1.2] 3.9% [3.4–4.4] 2.2% [1.9–2.6] 1.7% [1.5; 1.8] 1.9% [1.5–2.4] 1.9% [1.5–2.5] 0.0% [–0.2; 0.2]
 Sessile serrated polyps with LGD 0.1% [0.0–0.2] 0.0% [0.0–0.1] 0.1% [0.0; 0.1] 0.1% [0.0–0.3] 0.0% [0.0–0.1] 0.1% [0.1; 0.1] 0.0% [0.0–0.1] 0.0% [0.0–0.1] –0.0% [–0.0; 0.0]
 Sessile serrated polyps with HGD 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0]
 Traditional serrated adenomas 0.6% [0.4–0.8] 0.3% [0.2–0.4] 0.3% [0.3; 0.4] 0.8% [0.5–1.1] 0.3% [0.2–0.5] 0.5% [0.4; 0.5] 0.3% [0.2–0.6] 0.2% [0.1–0.4] 0.1% [0.1; 0.2]
  Traditional serrated adenomas with LGD 0.2% [0.1–0.3] 0.1% [0.0–0.1] 0.1% [0.1; 0.2] 0.2% [0.1–0.4] 0.1% [0.0–0.1] 0.1% [0.1; 0.2] 0.1% [0.1–0.4] 0.0% [0.0–0.1] 0.1% [0.1; 0.1]
  Traditional serrated adenomas with HGD 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0]
 Tubulovillous 2.4% [2.1–2.8] 1.7% [1.5–2.0] 0.7% [0.6; 0.8] 2.9% [2.5–3.3] 1.8% [1.5–2.1] 1.1% [1.0; 1.3] 1.6% [1.2–2.0] 1.5% [1.1–2.1] 0.0% [–0.1; 0.2]
  Tubulovillous with HGD 0.1% [0.1–0.2] 0.2% [0.1–0.3] –0.0% [–0.1; –0.0] 0.2% [0.1–0.3] 0.2% [0.1–0.4] –0.1% [–0.1; –0.0] 0.1% [0.0–0.2] 0.1% [0.0–0.2] 0.0% [–0.0; 0.1]
 Villous 0.2% [0.1–0.2] 0.2% [0.1–0.4] –0.1% [–0.1; –0.0] 0.2% [0.1–0.3] 0.1% [0.1–0.3] 0.0% [0.0; 0.1] 0.1% [0.0–0.2] 0.3% [0.1–0.7] –0.3% [–0.3; –0.2]
  Villous with HGD 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [–0.0; 0.0] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.1] 0.0% [–0.0; 0.0]
  Tubulous with HGD 0.2% [0.1–0.3] 0.2% [0.1–0.3] –0.0% [–0.0; 0.0] 0.2% [0.1–0.4] 0.2% [0.1–0.3] 0.0% [–0.0; 0.1] 0.0% [0.0–0.1] 0.1% [0.0–0.3] –0.1% [–0.1; –0.0]
 Polyp unspecified with HGD 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.0] 0.0% [0.0–0.1] 0.0% [0.0–0.0] 0.0% [0.0; 0.1] 0.0% [0.0–0.0] 0.0% [0.0–0.0] 0.0% [0.0; 0.0]